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Abstract 
 
Inhibition of anti-apoptotic BCL-2 has recently emerged as a promising new therapeutic strategy for 
the treatment of a variety of human cancers, including leukemia. Here, we used T-cell acute 
lymphoblastic leukemia as a model system to identify novel synergistic drug combinations with the 
BH3 mimetic venetoclax (ABT-199). In vitro drug screening in primary leukemia specimens that were 
derived from patients with high risk of relapse or relapse and cell lines revealed synergistic activity 
between venetoclax and the BET bromodomain inhibitor JQ1. Notably, this drug synergism was 
confirmed in vivo using T-ALL cell line and patient-derived xenograft models. Moreover, the 
therapeutic benefit of this drug combination might, at least in part, be mediated by an acute 
induction of the pro-apoptotic factor BCL2L11 and concomitant loss of BCL-2 upon BET bromodomain 
inhibition, ultimately resulting in an enhanced binding of BIM (encoded by BCL2L11) to BCL-2. 
Altogether, our work provides a rationale to develop a new type of targeted combination therapy for 
selected subgroups of high-risk leukemia patients.  
©    2017 Macmillan Publishers Limited. All rights reserved.
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Introduction 
 
T-cell acute lymphoblastic leukemia (T-ALL) arises from the malignant transformation of T-cell 
progenitors and accounts for about 15% of childhood and 25% of adult ALL cases(1). The cure rate for 
childhood T-ALL has steadily increased over the past decades, with current survival rates reaching 
approximately 85%(2, 3). Although these numbers are high, the clinical perspective for children that 
fail induction therapy or suffer from relapsed disease remains extremely poor, with only a 7-23% 
subset of relapsed T-ALL patients surviving beyond 3 to 5 years after the initial diagnosis(4). 
Compared to childhood leukemia, the clinical picture for adult T-ALL is even worse, with high relapse 
rates and long-term disease-free survival of about 40%(5-7). Altogether, these figures suggest that 
better and less toxic treatment strategies are urgently required to further improve the clinical 
management of childhood and adult T-ALL patients.  
Recently, we and other research groups reported promising therapeutic activity for venetoclax (ABT-
199), a highly specific inhibitor of the anti-apoptotic protein BCL-2, in immature subtypes of human 
T-ALL(8-10). Nevertheless, venetoclax sensitivity is variable between different T-ALL patient samples 
and the emergence of resistance to venetoclax(11-13) as well as the occurrence of dose-limiting 
toxicities(14) provides a rationale for the evaluation of venetoclax as part of a combination therapy. 
Indeed, previous studies have shown that venetoclax can synergize with conventional 
chemotherapeutic agents in human T-ALL, including doxorubicin, L-asparaginase, dexamethasone 
and cytarabine(8, 9). Venetoclax has recently also been approved by the FDA for the treatment of 
chronic lymphocytic leukemia (CLL). Indeed, clinical trials demonstrated progress-free survival in 
more than two thirds of relapsed CLL patients(14), including poor prognostic CLL patients that carry a 
17p deletion(15). Nevertheless, complete remission remained uncommon(14), further reinforcing 
the need for the evaluation of combined therapeutic strategies. 
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Bromodomains of the bromodomain and extra-terminal (BET) protein family recognize ɛ-N-
acetylation of lysine residues on histone tails. BRD4 is an important BET protein that recruits the 
positive transcription elongation factor complex (P-TEFb) to acetylated chromatin(16). The 
transcriptional coactivators BRD4 and Mediator co-occupy enhancers and promoters of active genes 
and are enriched at large stretches of enhancer sequences, often termed super-enhancers(17-19). 
Notably, these enhancers regulate the expression of critical oncogenes in a variety of human cancers, 
providing a rationale for the use of BET bromodomain inhibitors, such as JQ1, as powerful anti-cancer 
agents(17-19). Also in T-ALL, BET bromodomain inhibitors have shown therapeutic efficacy in a 
number of in vitro and in vivo model systems and were shown to inhibit the expression of the T-ALL 
oncogene MYC(20-22). In addition, super-enhancers have been identified in a panel of T-ALL cell lines 
near putative oncogenes, including MYB, TAL1, CDK6 and NOTCH1(18).  
In this study, we identified synergistic drug combinations with the BH3 mimetic venetoclax in the 
context of human T-ALL. Most notably, we show that combined targeting of BCL-2 and BET 
bromodomain proteins synergistically affects leukemic tumor growth in T-ALLs that were resistant to 
conventional chemotherapeutic agents. 
Materials and methods 
 
Primary patient samples  
Primary human ALL cells were recovered from cryopreserved bone marrow aspirates of patients 
enrolled in the ALL-BFM 2000, 2009 and ALL-REZ-BFM 2002 study. Informed consent was given in 
accordance with the Declaration of Helsinki and the ethics commission of the Kanton Zurich 
(approval number 2014-0383). Samples were classified as standard risk (SR), medium risk (MR), high 
risk (HR), very high risk (VHR) or relapse samples (R) according to the clinical criteria used in ALL-BFM 
2000(23). 
©    2017 Macmillan Publishers Limited. All rights reserved.
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Drug-screening platform  
The in vitro drug response of T-ALL primary patient samples was assessed in co-culture with hTERT-
immortalized primary bone marrow mesenchymal stromal cells (MSC) as described previously (23). 
Details are provided in the supplementary data.  
Cell lines  
Cell lines were purchased from the DSMZ repository (Braunschweig, Germany), except for CUTLL1 
(gift Prof. Adolfo Ferrando, Columbia University) and KOPTK1 (gift Prof. Hans-Guido Wendel, 
Memorial Sloan Kettering Cancer Center). Cells were cultured in RPMI 1640 medium (Life 
Technologies, Carlsbad, CA, USA; 52400-025) supplemented with 10% or 20% FBS, 100 U/ml penicillin, 
100 µg/ml streptomycin (Life Technologies, 15140-148), 100 µg/ml kanamycin sulfate (Life 
Technologies, 15160-047) and 2 mM L-glutamine (Life Technologies, 25030024) at 37°C with 5% CO2. 
In vitro evaluation of synergism between venetoclax and JQ1 in human T-ALL cell lines and primary 
samples  
The treatment of the cell lines with venetoclax (BioVision, Milpitas, CA; 2253-1) and/or (+)-JQ1 (BPS 
Bioscience, San Diego, CA, USA; 27401) and viability measurements via the CellTiter Glo Viability 
assay (Promega, Madison, WI, USA) have previously been described in Peirs et al.(8) CalcuSyn 
software (Biosoft, Cambridge, United Kingdom) was used to calculate the combination index (CI) with 
the Chou-Talalay method. The reported CI is the average of the values obtained at the ED50, ED75 
and ED90 point. Primary patient samples co-titration experiments were performed for selected drugs. 
T-ALL cell plates were prepared and handled in the same manner as for drug combination screening 
described above. Selected drugs in combination with venetoclax were dispensed using Tecan D300 
digital dispenser in a concentration matrix. The concentration range tested for venetoclax and JQ-1 
were determined for each patient based on initial drug response screening. CI was calculated using 
Chou-Talalay method as implemented in R package (https://github.com/xtmgah/DDCV). 
©    2017 Macmillan Publishers Limited. All rights reserved.
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Western blot  
Western blot analysis was performed as previously described(8). The primary antibodies used were 
Bcl-2 antibody (C-2) (1:500, Santa Cruz Biotechnology, Dallas, TX, USA; sc-7382), PARP-1 antibody (F-2) 
(1:1000, Santa Cruz Biotechnology, sc-8007), BIM antibody (1:1000, EMD Millipore, Darmstadt, 
Germany; AB17003), β-actin antibody (1:10000, Sigma-Aldrich, Saint Louis, MO, USA; Clone AC-75, 
A2228) and α-tubulin antibody (1:10000, Sigma-Aldrich, T5168). The detection of the blots was done 
with ChemiDoc-It Imaging System (UVP, Upland, CA, USA). Densitometric analysis of the protein 
bands was performed using ImageJ (NIH, Bethesda, MD, USA). Images have been cropped for 
presentation. 
AnnexinV/PI staining  
FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, San Jose, CA, USA; 556547) was used and 
samples were measured on the S3 cell sorter (Bio-Rad, Hercules, California, USA).  
Mice experiments  
Female nonobese diabetic/severe combined immunodeficient γ (NSG) mice were injected in the tail 
vein with 150µl PBS containing 5*106 luciferase-positive LOUCY cells(8), 5*106 ALL-SIL cells or 1*106 
cells from a secondary xenograft of patient T-VHR-26. Engraftment of the cells was followed by 
bioluminescence imaging as previously described(8) or by measuring the percentage of leukemic cells 
in the blood. Once there was clear engraftment (day 0), mice were randomly divided into four groups 
(control, venetoclax, JQ1 and combination) and treatment was started. Mice received daily 50mg 
venetoclax/kg body weight via oral gavage and/or 50mg JQ1/kg body weight via intraperitoneal 
injection. Venetoclax (Axon Medchem, Groningen, The Netherlands) was formulated in 60% phosal 
50 propylene glycol, 30% polyethylene glycol 400 and 10% ethanol. (+)-JQ1 (MedChem Express, 
South Brunswick Township, NJ, USA) was formulated in 10% DMSO and 90% of a 10% 2-
hydroxypropyl-β-cyclodextrin solution. At the end of the treatment period, blood was taken and mice 
were sacrificed. The percentage of leukemic cells was analyzed by staining the cells with an PE-
©    2017 Macmillan Publishers Limited. All rights reserved.
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labeled antibody for human CD45 (hCD45) (Miltenyi Biotec, Bergisch Gladbach, Germany; 130-098-
141), performing red blood cell lysis and measuring the percentage on a LSRII flow cytometer using 
FACSDiva software (BD Bioscience). The ethical committees on animal welfare at Ghent University 
Hospital and University Children’s Hospital Zurich approved all animal experiments. 
Gene expression profiling and GSEA  
LOUCY cells were treated with DMSO or (+)-JQ1. Three biological replicates of this treatment were 
performed and RNA was isolated using the miRNeasy mini kit (Qiagen, Venlo, The Netherlands) with 
on-column DNase digestion. RNA quality was evaluated by the Experion RNA StdSens analysis kit 
(Bio-Rad). RNA was amplified and labeled using the Low Input Quick Amp Labeling Kit, One Color 
(Agilent Technologies, Santa Clara, CA, USA; 5190-2305) and hybridized with the Gene Expression 
Hybridization Kit (Agilent Technologies, 5188-5242) to the SurePrint G3 Human Gene Expression 
Microarray G4851A (design ID 028004, Agilent Technologies). Normalization of microarray intensities 
was done using the variance stabilization and calibration (VSN, version 3.30.0) package in R (version 
3.0.2). Only probes with a signal 10% higher than the negative control probes were considered for 
analysis. Differential expression analysis was performed using the limma package (version 3.18.13) 
with p-value adjustment using the Benjamini and Hochberg method. The design matrix took into 
account the pairing information of the data. Enrichment analysis was performed with the MSigDB c2 
gene sets collection using the GSEA desktop application (Broad Institute, version v2.2.0) run with the 
default parameters and with gene set permutations. The data have been deposited in NCBI's Gene 
Expression Omnibus(24) and are accessible through GEO Series accession number GSE81918. 
Real-time quantitative PCR (RT-qPCR)  
The miRNeasy mini kit (Qiagen) and the RNAse-Free Dnase set (Qiagen) were used to isolate RNA. For 
determination of mRNA levels, cDNA synthesis was performed with the iScript Advanced cDNA 
synthesis kit (Bio-Rad). The SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) was used for the 
PCR reactions. Every sample was analyzed in duplicate and the gene expression was normalized 
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against 3 housekeeping genes. For quantification of mature miRNAs, the miScript II RT kit (Qiagen) 
and target-specific miScript Primer Assays (Qiagen) together with the miScript SYBR Green PCR Kit 
were used. All RT-qPCR reactions were run on the LightCycler 480 (Roche, Vilvoorde, Belgium) and 
qBasePLUS software (Biogazelle, Zwijnaarde, Belgium) was used for analysis. Primer sequences and 
miScript Primer Assays are listed in Supplementary Table 5. 
Co-immunoprecipitation 
Protein lysates were incubated with 2 μg of antibody. After 4h rotation at 4°C, 20 μl of Protein A 
UltraLink Resin (Thermo Scientific, Waltham, MA, USA; 53139) was added for overnight incubation at 
4°C. Beads were washed 3 times with RIPA buffer and immunoprecipitates were eluted by heating 
the beads at 95 °C in 2× SDS loading buffer (62 mM Tris–HCl (pH 6.8), 4% SDS, 20% glycerol, 0.01% 
BFB (bromophenol blue), 2.5% beta-mercaptoethanol) for 10 min. A part of the original lysates were 
similarly denaturated by heating at 95 °C for 10 min after adding 5× SDS loading buffer (155 mM Tris–
HCl (pH 6.8), 5% SDS, 32% glycerol, 0.025% BFB, 2,5% beta mercapto-ethanol). 
Modulation of BIM expression  
The pENTR223-BCL2L11 (LMBP ORF81079-A09) plasmid was available from the BCCM/LMBP Plasmid 
Collection(25) and was used to clone BCL2L11 in the pInducer21 plasmid(26). The MISSION lentiviral 
shBCL2L11 TRCN0000001051 (Sigma-Aldrich) vector (BCCM/LMBP Collection (25)), in which the 
puromycin resistance cassette was replaced by eGFP, was used to perform BIM knockdown. As non-
targeting shRNA control, MISSION pLKO.1-puro Non-Mammalian shRNA Control Plasmid (SHC002), in 
which also puro was replaced by eGFP, was used. Virus production was performed in HEK293TN cells 
using JetPEI polyplus with pMD2.G (envelope plasmid), psPAX2 (packaging plasmid) and target 
plasmid in 0.1/0.9/1 ratios. Transduced KARPAS-45 cells expressing GFP were selected by cell sorting. 
BCL2L11 expression was induced by adding doxycyclin (1µg/ml) and sensitivity to venetoclax was 
evaluated by adding venetoclax together with or without doxycycline for 48h to the cells. To evaluate 
©    2017 Macmillan Publishers Limited. All rights reserved.
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the effect of BIM knockdown, cells were treated with venetoclax, JQ1 or the combination for 48h. 
Viability was evaluated with CellTiter Glo as described above. 
Statistics 
GraphPad Prism 5.04 (La Jolla, CA, USA) was used for statistical analyses. 
Results 
Identification of synergistic drug combinations with venetoclax in primary human T-ALL 
Previous studies have shown promising anti-tumor activity for venetoclax in the context of human T-
ALL(8-10). However, drug responses have been variable across patients both in vitro as well as in 
xenografts, suggesting the need for predictive biomarkers and further investigation towards 
synergistic drug combinations with venetoclax. Given this, we took advantage of a drug-profiling 
platform(27) (Figure 1A) to test 21 clinically relevant compounds (Supplementary Table 1) for their 
ability to synergize with venetoclax in six primary human T-ALLs, including five diagnostic and one 
relapse specimen. Notably, the selected patient samples represented different molecular genetic 
subtypes of human T-ALL and displayed a variety of tumor immunophenotypes. In addition, they 
displayed variable levels of BCL-2 and BIM protein expression (Supplementary Figure 1A) and most 
of these high-risk T-ALL patient samples experienced significant levels of minimal residual disease 
upon first line therapy (Supplementary Table 2). 
First, we generated venetoclax response curves for each T-ALL sample and selected a sub-lethal dose 
of venetoclax for screening purposes (Figure 1A). Two T-ALL samples were sensitive at 
concentrations below 100nM, whereas the remaining cases were more resistant to venetoclax 
(Supplementary Figure 1B). This variability in venetoclax sensitivity amongst T-ALL patient samples 
corresponded to large differences in the area under the curve (AUC), a parameter that captures both 
IC50 and Emax as relevant endpoints of drug activity (Figure 1B). Next, we generated dose response 
curves (1nM, 10 nM, 100nM, 1µM and 10µM) for the 21 compounds in the presence or absence of a 
©    2017 Macmillan Publishers Limited. All rights reserved.
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sublethal dose of venetoclax (Figure 1A). The results of this initial screening are visualised by 
scatterplots of AUC values, in which decreased AUC upon addition of venetoclax is indicative of 
increased antileukemic activity (Figure 1B; Supplementary Figure 2). In line with previous studies, 
combination of venetoclax with conventional chemotherapeutic agents including vincristine, 
dexamethasone and etoposide increased therapeutic efficacy in some of the T-ALL cases analysed 
(Figure 1B). The strongest effects, however, were observed for the combination of venetoclax with 
JQ1, which resulted in reduced leukemic tumor growth in 5 out of 6 primary T-ALL patient samples 
(Figure 1B). As a confirmation, we validated responsive (Figure 1C) as well as non-responsive 
(Supplementary Figure 3) drug interactions identified in this initial screen. Altogether, this screening 
effort identified clinically relevant drugs that could increase the therapeutic efficacy of venetoclax in 
the context of T-ALL. 
Combined targeting of BCL-2 and BET bromodomain proteins in human T-ALL  
Given that our initial screen pointed towards increased efficacy of venetoclax upon BET 
bromodomain inhibition in a significant proportion of T-ALLs, we subsequently analysed the 
synergistic potential of this drug combination in more detail by performing co-titration experiments 
with individually-optimized concentration ranges in primary leukemias and a panel of human T-ALL 
cell lines.     
First, we determined the combination indexes (CI) for the 6 primary T-ALLs that were also used for 
the initial screening and identified synergistic activities (CI<1) between venetoclax and JQ1 in five out 
of six cases analysed (Figure 2A). Notably, similar results were obtained using OTX015 (MK-8628), 
another BET bromodomain inhibitor currently being tested in clinical trials for various tumor 
entities(28, 29) (Supplementary Figure 4). 
Next, we determined dose response curves in a panel of 13 human T-ALL cell lines with different BCL-
2 levels and varying sensitivities towards venetoclax (Figure 2B and Supplementary Figure 5). 
Notably, T-ALL cell lines displayed variable levels of synergism with the lowest CI values (strongest 
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synergism) detected for tumor lines with high BCL-2 expression (Figure 2B). Indeed, the combination 
index showed a negative correlation with BCL-2 protein levels in T-ALL cell lines (Figure 2C). 
Moreover, synergistic activity of this drug combination corresponded to increased cell death 
induction in T-ALL cell lines with low CI values (Supplementary Figure 6). 
Evaluation of the venetoclax and JQ1 combination therapy in xenograft models 
To evaluate the therapeutic potential of combined BCL-2 and BET bromodomain inhibition in human 
T-ALL, we subsequently performed in vivo drug treatment experiments using xenograft models. Four 
weeks after injection of luciferase-positive LOUCY cells(8) in immunodeficient mice, successful 
engraftment was confirmed by bioluminescence imaging and daily drug treatment was initiated (day 
1-13). Leukemia still progressed under JQ1 monotherapy (n=5), albeit to a lesser extent as compared 
to vehicle-treated control mice (n=8) (Figure 3A and Supplementary Figure 7). Mice treated for 13 
days with venetoclax alone (n=5) initially showed disease regression, but this therapeutic response 
was not durable (Figure 3A and Supplementary Figure 7). In contrast, combination of venetoclax 
with JQ1 (n=5) resulted in durable disease regression (Figure 3A-B). In line with these results, analysis 
of the percentage of human leukemic cells in peripheral blood and bone marrow as well as 
examination of the spleen size confirmed the superior therapeutic effect of this combination 
treatment (Figure 3C-D and Supplementary Figure 8). Of note, mice receiving JQ1 alone or in 
combination with venetoclax displayed significant weight loss (Supplementary Figure 8), a putative 
side effect of BET bromodomain inhibition.  The synergistic effect of combined BCL-2 and BET 
bromodomain inhibition was also confirmed in the TLX1 positive T-ALL cell line ALL-SIL 
(Supplementary Figure 9). The genetic characteristics of LOUCY and ALL-SIL are summarized in 
Supplementary Table 3. 
Finally, we performed a similar in vivo drug treatment experiment using a primary patient-derived 
xenograft. For this, leukemic cells from the very high risk T-ALL patient (T-VHR-26) were engrafted 
and treated with a similar drug regimen as mentioned above. Notably, this experiment confirmed the 
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superior therapeutic effect of combined BCL-2 and BET bromodomain inhibition for the treatment of 
this high risk T-ALL patient sample (Figure 4 and Supplementary Figure 10). Of note, in this 
experiment, no significant weight loss was observed in any of the treatment groups (Supplementary 
Figure 10C). 
Mechanistic insights into the synergistic activities of venetoclax and JQ1 in human T-ALL 
To understand how BET bromodomain inhibition might synergize with the BCL-2 inhibitor venetoclax, 
we subsequently analyzed the transcriptional consequences of JQ1 treatment in the T-ALL cell line 
LOUCY by microarray analysis. Short-term exposure to a low dose of JQ1 (4h, 250nM) provided 
insights in the genes whose expression was immediately affected by BET bromodomain inhibition 
(Figure 5A, left). In contrast, sustained exposure at a higher concentration (48h, 1µM) revealed 
broader transcriptional effects with more than half of the expressed probesets showing significant 
up- or downregulation (adj. p-value<0.05; Figure 5A, right). Significantly downregulated genes upon 
short-term drug treatment included stem-cell associated genes and putative oncogenes such as 
BAALC, WT1, MN1, MEF2C, LMO1 and LMO2, whereas other oncogenic factors, including BCL2, 
IGFBP7, ZEB2, GFI1B, MYB and LYL1, only changed significantly after 48h. 
In line with previous reports(17-19), these JQ1 responsive genes were regulated by strong and active 
enhancer elements characterized by broad binding of the H3K27ac histone mark in LOUCY cells(30) 
(Figure 5B). Indeed, genes associated with the 500 highest ranked enhancer regions in LOUCY were 
significantly enriched in genes downregulated after JQ1 treatment (Figure 5C). Moreover, 
enrichment analysis using gene sets from the Molecular Signatures database (MSigDB) revealed that 
genes upregulated after JQ1 in LOUCY cells significantly overlapped with genes activated upon HDAC 
inhibition (Figure 5D). In line with this notion, the Library of Integrated Cellular Signatures (LINCS) 
revealed a strong connection between the JQ1-induced expression signature in LOUCY and gene 
signatures induced by HDAC inhibitors (Supplementary Table 4).  
©    2017 Macmillan Publishers Limited. All rights reserved.
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Given that binding of the pro-apoptotic BIM (encoded by BCL2L11) to the BH3 domain of BCL-2 is an 
important mediator of venetoclax activity(31-34), we subsequently focused on the transcriptional 
effects of JQ1 on the expression of both factors. Notably, in LOUCY cells, BCL2L11 expression was 
induced after short-term JQ1 exposure (Figure 5A, left), whereas loss of BCL2 expression was only 
detected at later time points (Figure 5A, right). In addition, the expression of the miR17-92 cluster, a 
known negative regulator of BIM(35) was not affected after 4h of JQ1 treatment but was clearly 
downregulated after 48h (Supplementary Figure 11A). Upregulation of pro-apoptotic BCL2L11 and 
concomitant loss of anti-apoptotic BCL-2 could be confirmed in all T-ALL cell lines that displayed 
strong synergy (CI<0.5) for the ABT199/JQ1 drug combination. As a result, BET bromodomain 
inhibition triggered an increased BIM to BCL-2 ratio (Figure 6A and Supplementary Figure 11B), 
providing a putative explanation for the improved therapeutic efficacy of venetoclax upon JQ1 
treatment. Indeed, co-immunoprecipitation experiments demonstrated an increased BIM to BCL-2 
binding (Figure 6B) upon JQ1 treatment. Finally, doxycycline inducible overexpression of BIM in the 
KARPAS-45 cell line mimicked the effect of JQ1 and resulted in an increased sensitivity towards 
venetoclax (Figure 6C) while knockdown of BIM lowered the sensitivity to ABT-199, JQ1 and 
combination treatment (Figure 6D).  
Discussion 
Venetoclax is a promising new molecular therapy that is currently being evaluated in clinical trials for 
different hematological malignancies(14, 15, 36). However, the limited number of complete 
remissions(14) and the emergence of resistance with venetoclax as single agent prompts for a 
systematic evaluation of combinations with rationally-designed small molecules to assess its true 
therapeutic potential. Indeed, synergistic cytotoxic effects have been described for the combination 
of venetoclax with BTK(37-39), galectin(40), Aurora Kinase A(41), CDK(42, 43) and PI3K/AKT/mTOR 
inhibition(13, 44). 
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Given the promising single agent activity of venetoclax in human T-ALL subsets(8-10), we 
systematically evaluated clinically relevant drugs in order to identify synergistic combinations with 
venetoclax. The strongest and most consistent effect was detected for the combination with the 
bromodomain inhibitors JQ1 and OTX015, both targeting critical mechanisms that are deregulated in 
cancer cells. This effect could be validated in vivo using leukemia xenograft models. Notably, this 
concept has recently been suggested as an experimental therapy for double hit lymphoma, triple hit 
lymphoma and mantle cell lymphoma in which both MYC and BCL2 are deregulated(45-47). 
Interestingly, our preclinical data indicate that relevant activity can be obtained with this 
combination of agents irrespectively from their activity as single agent, which may possibly broaden 
the cohort of eligible cancer types (or subsets) for clinical translation. However, the challenge will be 
to identify useful biomarkers to better define patients that may benefit from such experimental 
combinations. Interestingly, an increase of BCL-2 protein levels in human T-ALL cell lines correlated 
with synergism between venetoclax and JQ1. Nevertheless, the value of additional methodologies 
such as BH3-profiling(48) should also be taken into consideration in future studies of this therapeutic 
rationale.  
The importance of BRD4 in processes that lead to abnormal activation of cancer driving genetic 
programs is increasingly being understood(17-19). The proof of concept in T-ALL was provided by 
studies of BET bromodomain inhibitors with a focus on MYC inhibition(20-22). Given the central 
importance of super-enhancer deregulation in cancer(18, 19), a similar principle may apply to many 
different transcriptional programs in leukemia cells. However, the broad transcriptional effects of 
these inhibitors on T-ALL cells remain largely unexplored. Gene expression profiling of LOUCY cells 
treated with JQ1 confirmed that BET bromodomain inhibition results in reduced expression of super-
enhancer-associated oncogenes as previously described by Lovén et al.(17). Similar effects have also 
previously been reported for the T-ALL cell line ALL-SIL(49). Although there is some overlap between  
super-enhancers in different T-ALL cell lines(18, 49), each cell line seems to have a pretty unique 
spectrum of super-enhancer sequences. However, we also observed acute gene activation within 4 
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hours of JQ1 treatment. In the gene signature that was activated upon JQ1 treatment in LOUCY cells, 
HDACi associated gene sets were enriched. This is in accordance with Bhadury et al.(50) who describe 
a large overlap between genes induced by BETi and HDACi.  
BCL2L11 (encoding BIM) is one of the genes that showed such an acute induction of gene expression 
upon JQ1 treatment in the context of T-ALL. BIM is an activator BH3-only pro-apoptotic protein that 
can directly interact with BAX and/or BAK to induce apoptosis. BCL-2 can prevent apoptosis by 
sequestering pro-apoptotic proteins such as BIM(51). Studies demonstrated the requirement for BCL-
2 complexed to the pro-apoptotic activator BIM in order to sensitize lymphoid cells to BCL-2 
inhibition by venetoclax or ABT-737(31-34). In our study, BET bromodomain inhibition increased BIM 
to BCL-2 binding, and could provide a putative explanation for the observed synergism between 
venetoclax and JQ1/OTX015 in the context of human T-ALL. Importantly, upregulation of pro-
apoptotic BIM upon JQ1 treatment has also been described in a variety of other tumor entities(52-
55), suggesting that the synergistic activity between these molecules might not be restricted to 
human T-ALL. Xu et al.(56) attributed the upregulation of BCL2L11 in response to JQ1 to the 
downregulation of the miR17-92 cluster. We also observed a downregulation of the miR17-92 cluster 
but not yet after 4h of JQ1 treatment, a timepoint with already significant upregulation of BCL2L11 in 
LOUCY. Therefore, this mechanism does not explain the acute upregulation of BCL2L11 but this could 
definitely contribute to sustain the upregulation of BCL2L11.  
In summary, our study provides a rationale to select patients with treatment resistant T-ALL for an 
innovative combination treatment based on mechanisms that are not exploited by conventional 
chemotherapy regimens. Interference with the balance between pro- and anti-apoptotic proteins in 
BCL2-dependent T-ALL using the combination BET bromodomain inhibition and the BCL2-inhibitor 
venetoclax should be considered in future clinical trials for this indication. 
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Figure Legends 
Figure 1 Drug-screening platform to identify novel synergistic combinations of venetoclax and 
other drugs 
(A) In a panel of primary T-ALL samples the effect of venetoclax treatment on cell viability was 
measured by flow cytometry using 7-AAD 72 hours after venetoclax treatment. Six 
representative samples (blue curves: sensitive to venetoclax; red curves: more resistant to 
venetoclax) were selected. For each sample, an optimal sub-lethal dose of venetoclax was 
calculated based on area under the curve (AUC) calculations of venetoclax as single agent. A 
single venetoclax dose was combined with selected clinically relevant compounds and the 
response change was compared to the control plate. Promising single compound 
combinations were validated in co-titration experiments.  
(B) (i.) Scatterplots representing response of T-ALL samples (N=6) to venetoclax alone, shown as 
area under the curve (AUC). (ii.) Responses of T-ALL patient samples to combination of a sub-
lethal venetoclax dose and indicated chemotherapeutic agents. AUC values of dose response 
curves from individual drug treatments (circles) or combined with venetoclax (triangles) are 
shown. 
(C) Representative examples of co-titration assays for compounds found to synergize with 
venetoclax in preselected T-ALL samples from initial combination screening. (i) 
topoisomerase I inhibitor topotecan, (ii) dual PI3K and mTOR inhibitor dactolosib and (iii) 
BRD4 inhibitor JQ1. 
Figure 2 In vitro synergism between venetoclax and JQ1 in primary patient samples and T-ALL cell 
lines 
(A) Dose response curves are given for co-titration assays in primary T-ALL samples with 
increasing concentrations of both venetoclax and the BRD4 inhibitor JQ1. Combination 
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indices (CIs) indicate synergism for five of the six cases, and additive activity for the 
remaining sample.  
(B) Overview of CIs between venetoclax and JQ1 in a panel of human T-ALL cell lines with 
indication of the degree of synergism. Mean and standard deviation of at least three 
independent experiments per cell line are represented. Western blot (bottom panel) 
indicates the BCL-2 protein levels in this cell line panel with β-actin as loading control. 
(C) Scatterplot demonstrating the correlation between BCL-2 protein level and CI in the T-ALL 
cell lines. 
Figure 3 Combination treatment of mice xenografted with luciferase-positive human LOUCY cells 
(A) Leukemic burden was followed during the experiment on the basis of the luminescence of 
the leukemia cells. For each treatment group, one mouse is represented from day 0 (i.e. the 
day before the treatment started) till day 14 (i.e. the end of the experiment). The graph 
shows the average and standard deviation of the total flux of luminescence for all the mice in 
the group relative to the signal on day 0.  
(B) Total flux of each mouse within a treatment group on day 14 relative to day 0.  
(C) Percentage of hCD45+ leukemic cells in the peripheral blood for each mouse. All viable cells 
after red blood cell lysis were selected based on the forward and side scatter parameters. 
One sample from the control group could not be analyzed correctly. 
(D) Percentage of hCD45+ leukemic cells in the bone marrow for each mouse. All the viable cells 
after red blood cell lysis were selected based on the forward and side scatter parameters.  
The one-tailed Mann-Whitney test was used to compare the treatment groups statistically. ns not 
significant, * P<0.05, ** P<0.01, *** P<0.001. Horizontal lines on the graph indicate the median for 
each group.  
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Figure 4 Combination treatment of patient (T-VHR-26)-derived xenograft 
(A) Percentage of hCD45+ leukemic cells in the peripheral blood for each mouse after 14 days of 
treatment 
(B) Percentage of hCD45+ leukemic cells in the bone marrow for each mouse after 14 days of 
treatment 
(C) Percentage of hCD45+ leukemic cells in the liver for each mouse after 14 days of treatment 
The one-tailed Mann-Whitney test was used to compare the treatment groups statistically. ns not 
significant, * P<0.05, ** P<0.01, *** P<0.001. Horizontal lines on the graph indicate the median for 
each group.  
Figure 5 Transcriptional effects of JQ1 on LOUCY 
(A) Volcano plots displaying the differentially expressed genes in LOUCY after 4h of treatment 
with 250nM JQ1 (left) and 48h of treatment with 1µM JQ1 (right). In case multiple probes for 
one gene were present on the array, the differentially expressed probe with largest fold 
change was plotted. 
(B) Hockey-stick plot showing the ranked H3K27Ac-seq signal of all enhancers in LOUCY. Super-
enhancers are indicated with blue dots. The red dots are examples of enhancers associated 
with interesting downregulated genes upon JQ1 treatment.  
(C) GSEA showing a significant enrichment of the genes associated with the top 500 super-
enhancers in LOUCY among the downregulated genes after treatment with 250nM JQ1 for 4h 
(top) or 1µM JQ1 for 48h (bottom).  The nearest TSS to each super-enhancer was determined 
via Peak Analyzer (OriginLab). This list of super-enhancer-associated genes was then used as 
a gene set for GSEA.  
(D) GSEA showing a significant enrichment of gene sets containing upregulated genes after 
HDACi among the upregulated genes after treatment of LOUCY with 250nM JQ1 for 4h. Left: 
DALESSIO_TSA_RESPONSE, i.e. top genes up-regulated in HEK293 cells in response to 
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trichostatin A (TSA). Right: PEART_HDAC_PROLIFERATION_CLUSTER_UP, i.e. cell proliferation 
genes up-regulated by histone deacetylase (HDAC) inhibitors SAHA and depsipeptide. 
Figure 6 Molecular insights in the mechanism of synergism 
(A) Western blot showing the increase of the BIM/BCL-2 protein ratio in synergistic T-ALL cell 
lines upon treatment with 1µM JQ1 for 48h. Only the upper band of BIM was quantified. 
(B) Immunoprecipitation with anti-BIM antibody illustrates the increased binding of BIM to BCL-2 
after JQ1 treatment. 
(C) Induction of BIM expression in KARPAS-45 pInducer21-BCL2L11 cells increases the sensitivity 
to venetoclax. The average and stdev from 3 independent experiments is plotted. Western 
blot shows BIM induction for 3 independent replicates. The doublet seen for BIMEL (largest 
isoform) may represent phosphorylation. 
(D) Knockdown of BIM in KARPAS-45 affects sensitivity to venetoclax, JQ1 and combination 
treatment. The average and stdev from 2 independent experiments is plotted. Western blot 
shows knockdown of BIM in the cells. 
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